Amneal Pharmaceuticals reported a net loss of $21.7 million
Amneal Pharmaceuticals (AMRX) filed a 10-Q with the SEC on Nov 9, 2026, 4:22 pm ET. Source: the filing on SEC EDGAR.
- Form
- 10-Q
- Filed
- Importance
- Major
- Accession
- 0001723128-26-000040
- Revenue of $862.68 million for the three months ended Sep 30, 2026
- Net loss of $21.7 million for the three months ended Sep 30, 2026
- Diluted EPS of -$0.06 for the three months ended Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
What changed since last quarter
1 new risk factor · 6 new legal mentions
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Revenue | $862.68M | $796.2M | +8.4% |
| Operating income and margin | $95.42M · 11.1% | $129.77M · 16.3% | −27%, margin −5.2 pts |
| Net income | −$21.7M | $57.66M | −138% |
| Operating cash flow | $98.3M | −$21.24M | +563% |
| Cash | $157.4M | $127.64M | +23% |
New risk factors (1)
- We may not realize the anticipated benefits of the Kashiv Acquisition, and the acquisition may increase our exposure to existing risks. +1 more paragraph
New legal mentions (6)
- These charges were partially offset by immaterial net credits related to several other legal matters. +1 more paragraph
- On August 4, 2026, the Court denied Defendants' joint motion for partial summary judgment on statute of limitations grounds as to certain federal claims, and on September 28, 2026, it denied the motion as to certain state-law claims. +3 more paragraphs
- On September 3, 2026, the Court granted CVS's motion to dismiss without prejudice. +1 more paragraph
- On October 9, 2026, the Company, Impax, and Sandoz entered into a settlement and license agreement to resolve their disputes. +1 more paragraph
- Two complaints were filed by purported shareholders of the Company against the Company and certain directors and officers of the Company related to the Company's agreement to acquire Kashiv Biosciences, LLC. The complaints were captioned: (i) Johnson v. Amneal Pharmaceuticals, Inc., et al., No. 654043/2026 (N.Y. Sup.
- and 1 more in the filing